Author:
Khalid S.,Calderon-Larranaga S.,Sami A.,Hawley S.,Judge A.,Arden N.,Van Staa T. P.,Cooper C.,Abrahamsen B.,Javaid M. Kassim,Prieto-Alhambra D.
Funder
National Osteoporosis Society
National Institute for Health Research Clinician Scientist award
NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference39 articles.
1. Sambrook P, Cooper C (2006) Osteoporosis. Lancet (London, England) 367(9527):2010–2018. https://doi.org/10.1016/S0140-6736(06)68891-0
2. National Institute for Health and Care Excellence (NICE) (2008) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. http://www.laalamedilla.org/GUIAS/Guia%20NICE%20osteoporosis%20P12011.pdf
3. Kang J-HJ-H, Keller JJ, Lin H-CH-C (2012) A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 23:2551–2557. https://doi.org/10.1007/s00198-012-1894-0
4. Huang B, Huang F, Gui Y et al (2015) Association between bisphosphonates therapy and incident myocardial infarction: meta-analysis and trial sequential analysis. J Cardiovasc Pharmacol 66:168–477
5. Kim DH, Rogers JR, Fulchino LA et al (2015) Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS ONE 10:e0122646. https://doi.org/10.1371/journal.pone.0122646
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献